UK govt’s £20m fund for life sciences opens for applications
08-04-2021
angelsolergollonet / Shutterstock.com
UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
fake medicines, medicines supply chain, counterfeit drugs, Brexit, Falsified Medicines Directive, ABPI
